Publications by authors named "H K Tomkinson"
Article Synopsis
- Osimertinib is a targeted therapy for EGFR-mutated non-small cell lung cancer that was evaluated for its effectiveness and safety based on plasma concentration levels in a large clinical study involving 1,689 patients.* -
- The analysis revealed that while osimertinib was more effective than other treatments regardless of dosage, there was no significant increase in efficacy with higher drug exposure, but a potential rise in side effects like interstitial lung disease, rash, and diarrhea.* -
- Overall, the findings suggest that higher doses of osimertinib (≥80 mg) may not provide additional benefits in treatment efficacy but could lead to more severe adverse effects, particularly in certain patient subgroups.*
Tyrosine kinase inhibitors (TKIs) are routinely prescribed for the treatment of non-small cell lung cancer (NSCLC). As with all medications, patients can experience adverse events due to TKIs. Unfortunately, the relationship between many TKIs and the occurrence of certain adverse events remains unclear.
View Article and Find Full Text PDFThis exploratory, post hoc analysis aimed to model circulating tumor DNA (ctDNA) dynamics and predict disease progression in patients with treatment-naïve locally advanced/metastatic epidermal growth factor receptor mutation (EGFRm)-positive non-small cell lung cancer, from the FLAURA trial (NCT02296125). Patients were randomized 1:1 and received osimertinib 80 mg once daily (q.d.
View Article and Find Full Text PDFTo define ruxolitinib failure and develop parameters to guide transition to next-line therapy for patients with myelofibrosis. A modified Delphi panel with 14 hematologists-oncologists. Survey concepts included defining primary refractory status, loss of response, disease progression, intolerance and transition to next-line therapy.
View Article and Find Full Text PDFOsimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor (TKI) recommended as first-line treatment for patients with locally advanced/metastatic EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, MET amplification/overexpression is a common acquired osimertinib resistance mechanism. Savolitinib is an oral, potent, and highly selective MET-TKI; preliminary data suggest that combining osimertinib with savolitinib may overcome MET-driven resistance.
View Article and Find Full Text PDF